Cumberland Pharmaceuticals Inc. (Cumberland) is a specialty pharmaceutical company that acquires, develops and commercializes branded prescription products. The company offers its products for the hospital acute care and gastroenterology markets. The company's product portfolio includes Acetadote (acetylcysteine), an injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen), an injection for the treatment of pain and fever; Kristalose (lactulose), a prescription laxative, for the treatment of chronic and acute constipation; Omeclamox-Pak, a riple therapy combination medication for Helicobacter pylori and duodenal ulcer disease; Vaprisol, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. Cumberland’s Ethyol is a cytoprotective drug containing amifostine for injection; Hepatoren (ifetroban), a Phase II candidate for the treatment of hepatorenal syndrome; Boxaban (ifetroban), a Phase II candidate for the treatment of patients with aspirin-exacerbated respiratory disease (AERD); Vasculan is used for the treatment of systemic sclerosis; Protaban is an oral formulation of ifetroban and the fourth development candidate in Cumberland’s pipeline; and Totect (dexrazoxane) is an emergency oncology intervention which is used to treat toxic effects of extravasation associated with anthracycline chemotherapy. The company’s Methotrexate injection is an approval submission candidate for the treatment of active rheumatoid, juvenile idiopathic and severe psoriatic arthritis, as well as severe disabling psoriasis. Cumberland’s partners include Phebra Pty Ltd; Teligent Pharmaceuticals, Inc.; DB Pharm Korea Co., Ltd.; Seqirus (a CSL company); Sandor Medicaids Pvt. Ltd.; GerminMED; PT. ETHICA Industri Farmasi; Laboratorios Grifols, S.A.; Gloria Pharmaceuticals Co. Ltd.; and Laboratorios Valmorca, C.A. The company's products are manufactured by third parties, which are overseen by Cumberland's quality control and manufacturing professionals. The company markets and sells approved products through its hospital and field sales forces in the US. Cumberland’s subsidiaries include Cumberland Emerging Technologies, Inc. and Cumberland Pharma Sales Corp.
Scope of the Report
-- About the Company - Historical Details, Current Ownership Structure and basic overview of Cumberland Pharmaceuticals Inc. in terms of revenue, net income, and operating income.
-- Financials - Details about Cumberland Pharmaceuticals Inc. listing status, annual financial reports (for the past 5 years), key financial highlights and region wise and category wise breakdown of their net revenue.
-- Products / Services - Listing of the company’s entire portfolio along with description of individual products / services providing a clear picture of their target audience.
-- Company SWOT Analysis - Outlines Cumberland Pharmaceuticals Inc.’s strengths, weaknesses, and opportunities and threats facing the company.
-- Recent Developments - Showcases Cumberland Pharmaceuticals Inc.’s recent developments including mergers, acquisitions, partnerships, collaborations, new product launches, investment and divestment plans.
-- Strategic Evaluation - Provides an overview of Cumberland Pharmaceuticals Inc.’s corporate goals and strategic initiatives and evaluates their outcomes along with outlining any persisting legal issues and outlook of our in-house analyst panel on the particular company.
-- Technology Landscape - Details how the company allocates its IT budget across the core areas of its business, CIO/CTO Profile, Key IT Initiatives and Deals undertaken buy the company at present along with outlook.
Key Questions Answered
-- What domain does Cumberland Pharmaceuticals Inc. operate and what are key points about it?
-- What is the product / service portfolio of Cumberland Pharmaceuticals Inc.?
-- How has Cumberland Pharmaceuticals Inc. performed financially from the 2013?
-- How does Cumberland Pharmaceuticals Inc. rank among its peers in terms of revenue and market share?
-- What are Cumberland Pharmaceuticals Inc. strengths and weaknesses and what opportunities and threats does it face?
-- What are Cumberland Pharmaceuticals Inc.’s main growth strategies and how successful has the company been at implementing them?
-- What is the in-house technical capability of Cumberland Pharmaceuticals Inc.? Where does it procure / outsource it?
Reasons to buy
-- Report delivered in easily accessible PPT format which can be used to gain insights quickly and further prepare presentations of your own
-- Lean pricing structure ultimately giving you vast access to the unlimited knowledge repository of the company profiles at very competitive cost
-- 12 hour delivery time fulfilling your urgent requests as per your requirement
-- On-demand customization options that can completely cater to your needs by focusing the report onto given specifics
1. About the Company
1.1 History and Basic Facts
1.2 Ownership Structure and Key Executives
1.3 Head Office
1.4 Other Locations & Subsidiaries
1.5 List of Competitors
1.6 Employee Count & Distribution
2.1 Company Type (Listed / Unlisted)
2.2 Annual Statements
2.3 Key Financial Highlights
2.4 Region-wise Breakdown
3. Product / Services
4. SWOT Analysis
4.1 SWOT Overview
5. Recent Developments
5.1 Mergers & Acquisitions
5.2 Partnerships, Collaborations & Joint Ventures
5.3 New Product Launches
5.4 Business Expansion / Divestment
6. Strategic Evaluation
6.1 Corporate Strategy
6.2 Legal Issues
6.3 Analyst Outlook
7. Technology Landscape
-- 7.1.1 Industry Snapshot
-- 7.1.2 IT Spend
-- 7.1.3 Key Information Technology Trends
-- 7.2.1 IT Overview
-- 7.2.2 Key IT Technologies
-- 7.2.3 Recent IT Initiatives
-- 7.2.4 IT Outsourcing Engagements
-- 7.2.5 Key IT Management
-- 7.2.6 CIO/CTO Profile
-- About Us
-- Contact Us
Fig.1: Company Snapshot
Fig.2: Locations Listing on Map
Table.1: Ownership Structure
Table.2: List of Competitors
Table.3: Annual Statements
Table.4: Key Financial Highlights
Table.5: Region-wise Breakdown
Table.6: Product/Services Overview
Table.7: Mergers & Acquisitions
Table.8: Partnerships, Collaborations & Joint Ventures
Table.9: New Product Launches
Table.10: Business Expansion / Divestment
Table 11: IT Budgets
Table 12: Key IT Management (CIO / CTO)
Table 13: IT Deals undertaken in the past years